Pegylated α-interferon-2a plus ribavirin compared with pegylated α-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: Prospective, non-randomized study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 6, 2008, Pages 861-866

  Escudero, Amparo ^a,b   Rodríguez, Felicidad ^b   Serra, Miguel A ^b   Del Olmo, Juan A ^b   Montes, Francisco ^c   Rodrigo, José M ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b University Hospital Clinic   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Administration and dosage; Antiviral agent; Chronic hepatitis C virus; Pegylated interferon 2a; Pegylated interferon 2b; Ribavirin; Viral load; Viral therapy

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; STEATOSIS;

EID: 44949261384     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05397.x     Document Type: Article

References (21)

1. Strader DB, Wright T, Thomas DL, Seeff LB. American association for the study of liver diseases practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39: 1147 71.
2. Glue P, Fang JW, Rouzier-Panis R et al. Hepatitis C Intervention Therapy Group. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 2000 68: 556 7.
3. Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001 61: 2263 8.
4. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin. Liver Dis. 2003 23 (Suppl. 1 23 8.
5. National Institutes of Health Consensus Conference Statement June 10-12, 2002. Management of Hepatitis C. 2002. Cited 9 July 2007. Available at URL: http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm
6. Von Wagner M, Huber M, Berg T et al. Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis. Gastroenterology 2005 129: 522 7.
7. Silva M, Poo J, Wagner F et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J. Hepatol. 2006 45: 204 13.
8. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am. J. Surg. Pathol. 1995 19: 1409 17.
9. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358: 958 65.
10. Fried MW, Shiffman ML, Reddy KR et al. Peg-IFN alpha 2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002 347: 975 82.
11. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004 140: 346 55.
12. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol. Assess. 2004 8: iii iv, 1 125.
13. Sullivan SD, Jensen DM, Bernstein DE et al. Cost-effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C. Am. J. Gastroenterol. 2004 99: 1490 6.
14. Almasio PL, Cavalletto L, Chemello L et al. Efficacy of PEG-IF alfa-2b vs. PEG-IFN alfa-2a + ribavirin regimens in treatment of naïve chronic HCV patients: a cumulative meta-analysis of retrospective date from 6 clinical sites. J. Hepatol. 2005 42 (Suppl. 1 671A.
15. Malone DC, Tran TT, Poordad FF. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. J. Manag. Care Pharm. 2005 11: 687 94.
16. Sporea I, Danila M, Sirli R, Popescu A, Laza A, Baditoiu L. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. J. Gastrointest. Liver Dis. 2006 15: 125 30.
17. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. J. Viral Hepat. 2007 14: 721 9.
18. Fuentes J, Sanchez E, Uribarrena-Amezaga R et al. Estudio comparativo retrospectivo de la eficacia de los interferones pegilados en el tratamiento de la hepatitis crónica C en la práctica clínica habitual. Gastroenterol. Hepatol. 2007 30 (Suppl. 1 176.
19. Cozzolongo R, Sartori M, Lanzilotta E, Tonello N, Manghisi OG. Comparison between the two peginterferons alfa in the treatment of chronic hepatitis C. Poster 563. 41st Annual Meeting of the European Association for the Study of the Liver. Cited 11 July 2007. Available at URL: http://www.easl.ch/easl2006/ program/session1.asp
20. Fumaz CR, Muñoz-Moreno JA, Ballesteros AL et al. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care 2007 19: 138 45.
21. Yu ML, Dai CY, Lee LP et al. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon alpha plus ribavirin combination therapy. Antivir. Ther. 2006 11: 1015 9.